NCT06227221View on ClinicalTrials.gov

Efficacy and Safety of Sorafenib in New-Onset Type 1 Diabetes Mellitus

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

October 31, 2025

Study Completion Date

June 30, 2028

Conditions
Type 1 Diabetes
Interventions
DRUG

Sorafenib

Subjects receive sorafenib 400mg once daily. Insulin therapy will be continued as a routine therapy.

DRUG

Placebo

Subjects receive placebo 400mg once daily. Insulin therapy will be continued as a routine therapy.

All Listed Sponsors
lead

Second Xiangya Hospital of Central South University

OTHER

NCT06227221 - Efficacy and Safety of Sorafenib in New-Onset Type 1 Diabetes Mellitus | Biotech Hunter | Biotech Hunter